Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKWBNA)

Drug Name

MOD-5023 Drug Info

Synonyms

Factor VII-CTP; FactroVIIa-CTP; Long-acting Factor VIIa (injectable/CTP, hemophilia), PROLOR; Long-acting Factor VIIa (peptide/injectable, hemophilia), PROLOR

Indication

Disease Entry	ICD 11	Status	REF
Hemophilia	3B10.0	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMKWBNA

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor VII (F7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Factor viia	DMZUW6P	Hemophilia	3B10.0	Approved	[1]
Vatreptacog alfa (activated)	DMANKTO	Bleeding disorder	GA20-GA21	Phase 3	[2]
BAX-817	DMB147A	Hemophilia	3B10.0	Phase 3	[3]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[4]
Recombinant factor VIIa PEGylated liposomal	DMY3TAD	Factor VII deficiency	3B14	Phase 1/2	[1]
F-7TG	DML4JXZ	Hemophilia	3B10.0	Phase 1	[1]
Eptacog alfa	DMAQYRL	Hemophilia	3B10.0	Phase 1	[5]
CB-813	DMXQGKL	Hemophilia	3B10.0	Phase 1	[6]
BAY 86-6150	DM6R3WC	Hemophilia	3B10.0	Discontinued in Phase 2/3	[7]
RNAPc2	DME9V0I	Colorectal cancer	2B91.Z	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor VII (F7)	TTF0EGX	FA7_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
2	Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
3	Clinical pipeline report, company report or official report of Baxter.
4	ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
5	Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
6	Clinical pipeline report, company report or official report of Catalyst Biosciences.
7	Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008.
8	rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16.